Video

Dr. Bhalla on Sensitizing TNBC to PARP Inhibitors and Cisplatin

Kapil N. Bhalla, MD, from the University of Kansas Cancer Center, describes an in vivo study that examined treatment with histone deacetylase inhibitors in triple-negative breast cancer cells.

Kapil N. Bhalla, MD, chief of personalized cancer medicine at the University of Kansas Cancer Center in Kansas City, describes the findings from an in vitro study that examined treatment with histone deacetylase (HDAC) inhibitors in triple-negative breast cancer (TNBC) cells.

Treatment with pan-HDAC inhibitors such as vorinostat and panobinostat can induce Hsp90 hyperacetylation, which causes depletion in BRCA levels and other DNA response proteins. This treatment produces a DNA repair deficit within the TNBC cells while also causing DNA damage. This results in a treatment scenario that mimics what is observed with BRCA mutations.

Bhalla adds that inducing BRCAness from treatment with a HDAC inhibitor allows for effective combination strategies with PARP inhibitors or cisplatin. These combinations could result in a synergistic treatment approach in TNBC.

This study provides the rationale to test cisplatin, HDAC, and PARP inhibitor combination strategies in patients with TNBC with or without the presence of a BRCA1/2 mutation.

<<<

View coverage from the 2012 SABCS

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies
Audio

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Jun 18th 2025 - Jun 19th 2026

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity